Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma (Review)

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 612-618

  Kobayashi, Hiroshi ^a   Sugimoto, Hitomi ^a   Onishi, Shunsuke ^a   Nakano, Kazutoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Gene expression profiling; Ovarian clear cell carcinoma; Proteomics

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR 54; MUCIN; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RETINOBLASTOMA BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BLOOD CLOTTING; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLEAR CELL CARCINOMA; EXTRACELLULAR MATRIX; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; ONCOGENE NEU; OVARIAN CLEAR CELL CARCINOMA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; REVIEW; SEROLOGY; SIGNAL TRANSDUCTION;

EID: 84931429065     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3367     Document Type: Review

References (76)

1. Jacobs IJ and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355-366, 2004.
2. Nozawa S, Yajima M, Sakuma T, et al: Cancer-associated galactosyltransferase as a new tumor marker for ovarian clear cell carcinoma. Cancer Res 50: 754-759, 1990.
3. Haruta S, Furukawa N, Yoshizawa Y, et al: Molecular genetics and epidemiology of epithelial ovarian cancer (Review). Oncol Rep 26: 1347-1356, 2011.
4. Gadducci A, Lanfredini N and Tana R: Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol 30: 612-617, 2014.
5. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. Radiographics 31: 625-646, 2011.
6. Ahmed AA, Etemadmoghadam D, Temple J, et al: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56, 2010.
7. Uekuri C, Shigetomi H, Ono S, Sasaki Y, Matsuura M and Kobayashi H: Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review). Oncol Lett 6: 1163-1173, 2013.
8. Shimizu M, Nikaido T, Toki T, Shiozawa T and Fujii S: Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 85: 669-677, 1999.
9. Shigetomi H, Sudo T, Shimada K, et al: Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: Chemosensitivity is regulated by checkpoint kinase CHK1. Int J Gynecol Cancer 24: 838-843, 2014.
10. Shigetomi H, Higashiura Y, Kajihara H and Kobayashi H: A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecol Endocrinol 28: 897-902, 2012.
11. Gütgemann I, Lehman NL, Jackson PK and Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol 21: 445-454, 2008.
12. Min KW, Park MH, Hong SR, et al; Gynecologic Pathology Study Group of the Korean Society of Pathologists. Clear cell carcinomas of the ovary: A multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol 32: 3-14, 2013.
13. Arnason T, Pino MS, Yilmaz O, et al: Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice. Cancer Biol Ther 14: 672-678, 2013.
14. Lin F, Zhang PL, Yang XJ, et al: Human kidney injury molecule-1 (hKIM-1): A useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 31: 371-381, 2007.
15. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS and Mok SC: Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67: 291-299, 2004.
16. Kaneuchi M, Sasaki M, Tanaka Y, et al: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316: 1156-1162, 2004.
17. Alkatout I, Friemel J, Sitek B, Anlauf M, Eisenach PA, Stühler K, Scarpa A, Perren A, Meyer HE, Knoefel WT, et al: Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol 28: 69-79, 2015.
18. Byrne JA, Maleki S, Hardy JR, et al: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 10: 497, 2010.
19. Campbell IG, Russell SE, Choong DY, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681, 2004.
20. Kuo KT, Mao TL, Jones S, et al: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601, 2009.
21. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: Their roles in tumor progression and prognostication of the patient. Mod Pathol 24: 1146-55, 2011.
22. Sugita S, Morishita Y, Kano J, Furuya S, Shiba-Ishii A and Noguchi M: IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. Histopathology 58: 729-738, 2011.
23. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol 19: 1149-1156, 2006.
24. Bell JL, Wächter K, Mühleck B, et al: Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70: 2657-2675, 2013.
25. Boonjaraspinyo S, Boonmars T, Wu Z, et al: Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 33: 1785-1802, 2012.
26. Yamamoto S, Tsuda H, Takano M, et al: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol 21: 115-124, 2008
27. Prentice LM, Klausen C, Kalloger S, et al: Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 15: 5-33, 2007.
28. Canbay E, Ergen A, Bugra D, et al: Kisspeptin-54 levels are increased in patients with colorectal cancer. World J Surg 36: 2218-2224, 2012.
29. Fujimura M, Katsumata N, Tsuda H, et al: HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: Possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93: 1250-1257, 2002.
30. Taniguchi F, Itamochi H, Harada T and Terakawa N: Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary. Int J Gynecol Cancer 23: 791-796, 2013.
31. Maretzky T, Le Gall SM, Worpenberg-Pietruk S, et al: Src stimulates fibroblast growth factor receptor-2 shedding by an ADAM15 splice variant linked to breast cancer. Cancer Res 69: 4573-4576, 2009.
32. Li W, Wang H, Jin X and Zhao L: Loss of RhoGDI is a novel independent prognostic factor in hepatocellular carcinoma. Int J Clin Exp Pathol 6: 2535-2541, 2013.
33. Canet B, Pons C, Espinosa I and Prat J: Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. Hum Pathol 42: 833-839,2011.
34. Clayton EF, Ziober A, Yao Y and Bing Z. Malignant tumors with clear cell morphology: A comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury. Ann Diagn Pathol 17: 192-197, 2013.
35. Tsuchiya A, Sakamoto M, Yasuda J, et al: Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512, 2003.
36. Senkel S, Lucas B, Klein-Hitpass L and Ryffel GU: Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731: 179-190, 2005.
37. Hirasawa A, Saito-Ohara F, Inoue J, et al: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004, 2003.
38. Liang L, Li Q, Huang LY, Li W, Wang YW, Li XX and Cai SJ: Loss of ARHGDIA expression is associated with poor prognosis in HCC and promotes invasion and metastasis of HCC cells. Int J Oncol 45: 659-666, 2014.
39. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P and Kalir T: Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 94: 2935-2940, 2002.
40. Nomura H, Tamada Y, Miyagi T, et al: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: Its relationship with T factor of pTNM classification. Oncol Res 16: 289-297, 2006.
41. Sönmez H, Süer S, Güngör Z, Baloglu H and Kökoglu E: Tissue and serum sialidase levels in breast cancer. Cancer Lett 136: 75-78,1999.
42. Spowart JE, Townsend KN, Huwait H, et al: The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathol 228: 437-447, 2012.
43. Cuff J, Salari K, Clarke N, Esheba GE, Forster AD, Huang S, West RB, Higgins JP, Longacre TA and Pollack JR: Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One 8: e74562, 2013.
44. Kato M, Yamamoto S, Takano M, Matsubara O and Furuya K: Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. Int J Gynecol Pathol 31: 2542-63, 2012.
45. Mahata P: Biomarkers for epithelial ovarian cancers. Genome Inform 17: 184-193. 2006.
46. Lin F, Shi J, Liu H, et al: Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: A useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol 129: 592-605, 2008.
47. Mehla K and Singh PK: MUC1: A novel metabolic master regulator. Biochim Biophys Acta 1845: 126-135, 2014.
48. Li B, Jin H, Yu Y, et al: HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer 19: 1347-1352, 2009
49. Miyamoto M, Takano M, Iwaya K, et al: X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer 110: 2881-2886, 2014.
50. Skirnisdottir I, Bjersand K, Akerud H and Seidal T: Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer 13: 524, 2013.
51. Jiang L, Siu MK, Wong OG, et al: iASPP and chemoresistance in ovarian cancers: Effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res 17: 6924-6933, 2011.
52. Maeda D, Ota S, Takazawa Y, et al: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 22: 824-832, 2009.
53. Suzuki S, Yoshikawa T, Hirosawa T, et al: Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 102: 1622-1629, 2011.
54. Tsuda H, Ito YM, Ohashi Y, et al: Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11: 6880-6888, 2005.
55. Lee HJ, Do JH, Bae S, et al: Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. Med Oncol 28 (Suppl 1): S522-S527, 2011.
56. Miao Y, Cai B, Liu L, Yang Y and Wan X: Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 19: 1545-1549, 2009.
57. Kuroda T, Hirohashi Y, Torigoe T, et al: ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One 8: e65158, 2013.
58. Kato N, Toukairin M, Asanuma I and Motoyama T: Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): A marker for ovarian clear cell carcinoma. Diagn Cytopathol 35: 193-197, 2007.
59. Arakawa N, Miyagi E, Nomura A, et al: Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. J Proteome Res 12: 4340-4350, 2013.
60. Abu Saadeh F, Norris L, O'Toole S, et al: Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk. Thromb Res 132: 627-634, 2013.
61. Yamamoto S, Konishi I, Mandai M, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227, 1997.
62. Yoffou PH, Edjekouane L, Meunier L, et al: Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. PLoS One 6: e20705, 2011.
63. Quattrocchi L, Sisson M, Green A, Martin SG, Durrant L and Deen S: Expression of angiogenic chemokines in ovarian clear cell carcinoma. J Obstet Gynaecol Res 39: 297-304, 2013.
64. Suh EJ, Kabir MH, Kang UB, et al: Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Exp Mol Med 44: 36-44, 2012.
65. Sundar IK, Yao H and Rahman I: Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal 18: 1956-1971, 2013.
66. Samartzis EP, Noske A, Dedes KJ, Fink D and Imesch P: ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 14: 18824-18849, 2013.
67. Nishimura S, Tsuda H, Ito K, et al: Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer 20: 220-226, 2010.
68. Balan V, Wang Y, Nangia-Makker P, et al: Galectin-3: A possible complementary marker to the PSA blood test. Oncotarget 4: 542-549, 2013.
69. Ho CM, Lai HC, Huang SH, Chien TY, Lin MC and Chang SF: Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest 40: 310-318, 2010.
70. Saeki H, Hashizume A, Izumi H, et al: The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncol Lett 4: 637-641, 2012.
71. Ho CM, Cheng WF, Lin MC, et al: Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 20: 1490-1497, 2010.
72. Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A and Hiramatsu Y: Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep 23: 917-925, 2010.
73. Yamaguchi K, Mandai M, Oura T, et al: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752, 2010.
74. Kato N, Sasou S, Teshima S and Motoyama T: Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary. Virchows Arch 450: 273-278, 2007.
75. Akahane T, Sekizawa A, Okuda T, Kushima M, Saito H and Okai T: Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol 24: 369-376, 2005.
76. Oe S, Hasegawa K, Nagase S, Kato R, Torii Y and Udagawa Y: Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol 29: 405-410, 2010.